Thermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities

Thermo Fisher Scientific experienced a sharp post-Q1 selloff despite beating sales and EPS expectations and raising full-year guidance. Inorganic growth from recent acquisitions, notably Clario, contributed materially to raised EPS guidance and overall revenue outlook. Short-term headwinds in government/academic spending and diagnostics are not expected to derail Thermo's long-term growth strategy, supported by reshoring and AI adoption.